{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:54:43Z","timestamp":1777982083761,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["R01GM127558"],"award-info":[{"award-number":["R01GM127558"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI120749"],"award-info":[{"award-number":["R01AI120749"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201100023C"],"award-info":[{"award-number":["HHSN272201100023C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jconrel.2023.12.031","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T14:12:55Z","timestamp":1703859175000},"page":"18-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques"],"prefix":"10.1016","volume":"366","author":[{"given":"Fernanda P.","family":"Pons-Faudoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Capuani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Facchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Nehete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"DeLise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lane R.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrine Ying Xuan","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Ittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"Kimata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod N.","family":"Nehete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto C.","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Grattoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.12.031_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003651","article-title":"The revolving door of HIV care: revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals","volume":"18","author":"Ehrenkranz","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0010","doi-asserted-by":"crossref","first-page":"ofab283","DOI":"10.1093\/ofid\/ofab283","article-title":"The impact of COVID-19 on UNAIDS 90\u201390\u201390 targets: calls for new HIV care models","volume":"8","author":"Guaraldi","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0015","first-page":"103","article-title":"How does the Cov\u0131d-19 pandemic affect the target 90-90-90?","volume":"19","author":"Karaosmanoglu","year":"2021","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003649","article-title":"Ending AIDS as a public health threat by 2030: time to reset targets for 2025","volume":"18","author":"De Lay","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10544-019-0389-6","article-title":"Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases","volume":"21","author":"Pons-Faudoa","year":"2019","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0030","doi-asserted-by":"crossref","first-page":"2100214","DOI":"10.1002\/adtp.202100214","article-title":"Extending drug release from implants via transcutaneous refilling with solid therapeutics","volume":"5","author":"Di Trani","year":"2022","journal-title":"Adv, Therap."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0040","first-page":"939","article-title":"Social networks and barriers to ART adherence among young adults (18-24 years) living with HIV at selected primary health facilities of south-western Uganda: a qualitative study","volume":"13","author":"Ajuna","year":"2021","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3389\/fphar.2017.00831","article-title":"Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations","volume":"8","author":"Iacob","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/09540120600652303","article-title":"Stigma and social barriers to medication adherence with urban youth living with HIV","volume":"19","author":"Rao","year":"2007","journal-title":"AIDS Care"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0055","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3947\/ic.2021.0136","article-title":"Long-acting injectable antiretroviral agents for HIV treatment and prevention","volume":"53","author":"Kim","year":"2021","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","volume":"77","author":"Thoueille","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0075","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","volume":"7","author":"Sch\u00fcrmann","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00744-17","article-title":"H.I.V.S.G. University of Washington\u2013Dakar, MK-8591 (4\u2032-ethynyl-2-fluoro-2\u2019-deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture","volume":"61","author":"Wu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0090","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/v13081566","article-title":"Islatravir is not expected to be a victim or perpetrator of drug-drug interactions via major drug-metabolizing enzymes or transporters","volume":"13","author":"Bleasby","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0095","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41591-021-01479-3","article-title":"Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial","volume":"27","author":"Matthews","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000003135","article-title":"A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque Islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection","volume":"92","author":"Matthews","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0105","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/COH.0000000000000591","article-title":"Long-acting implants to treat and prevent HIV infection","volume":"15","author":"Weld","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0115","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1038\/s41467-018-06490-w","article-title":"Ultra-long-acting removable drug delivery system for HIV treatment and prevention","volume":"9","author":"Kovarova","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100981","article-title":"Viral load reduction in SHIV-positive nonhuman primates via long-acting subcutaneous tenofovir alafenamide fumarate release from a nanofluidic implant","volume":"12","author":"Pons-Faudoa","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2023.12.031_bb0125","doi-asserted-by":"crossref","first-page":"2000163","DOI":"10.1002\/adtp.202000163","article-title":"Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates","volume":"4","author":"Pons-Faudoa","year":"2020","journal-title":"Adv. Therap."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","article-title":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","volume":"286","author":"Chua","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052880","article-title":"CAPRISA 018: a phase I\/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women","volume":"12","author":"Gengiah","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0175","doi-asserted-by":"crossref","first-page":"eadg2887","DOI":"10.1126\/scitranslmed.adg2887","article-title":"Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates","volume":"15","author":"Pons-Faudoa","year":"2023","journal-title":"Sci. Translat. Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0285","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1742-4690-7-88","article-title":"Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation","volume":"7","author":"Biesinger","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0290","first-page":"254","volume":"36","author":"Polacino","year":"2007","journal-title":"Immunogenicity and protective efficacy of Gag\/Pol\/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0295","volume":"64","author":"Su","year":"2020","journal-title":"A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0300","series-title":"WHO Expert Committee on Biological Standardization: Sixty-Sixth Report","author":"W.H.O.E.C.o.B. Standardization","year":"2016"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0145","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/s41467-018-04133-8","article-title":"Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale","volume":"9","author":"Bruno","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0150","doi-asserted-by":"crossref","first-page":"12246","DOI":"10.1021\/acsami.9b19182","article-title":"Finite-size charged species diffusion and pH change in nanochannels","volume":"12","author":"Di Trani","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2018.11.002","article-title":"Nanofluidic microsystem for sustained intraocular delivery of therapeutics","volume":"16","author":"Di Trani","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0160","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1039\/C9LC00394K","article-title":"Remotely controlled nanofluidic implantable platform for tunable drug delivery","volume":"19","author":"Di Trani","year":"2019","journal-title":"Lab Chip"},{"issue":"31","key":"10.1016\/j.jconrel.2023.12.031_bb0165","doi-asserted-by":"crossref","first-page":"35400","DOI":"10.1021\/acsami.2c08809","article-title":"Comprehensive analysis of electrostatic gating in nanofluidic systems","volume":"14","author":"Di Trani","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.031_bb0170","doi-asserted-by":"crossref","first-page":"2100214","DOI":"10.1002\/adtp.202100214","article-title":"Extending drug release from implants via transcutaneous refilling with solid therapeutics","volume":"5","author":"Di Trani","year":"2021","journal-title":"Adv. Therap."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0180","series-title":"17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy","first-page":"8","article-title":"Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques","author":"Grobler","year":"2016"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0190","unstructured":"D. Sch\u00fcrmann, D.J. Rudd, S. Zhang, I. De Lepeleire, M. Robberechts, E. Friedman, C. Keicher, A. H\u00fcser, J. Hofmann, J.A. Grobler, S.A. Stoch, Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0000000000002755","article-title":"Safety and pharmacokinetics of once-daily multiple-dose administration of islatravir in adults without HIV","volume":"88","author":"Matthews","year":"2021","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0200","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41467-019-10047-w","article-title":"Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection","volume":"10","author":"Radzio-Basu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0205","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/pharmaceutics12100981","article-title":"Viral load reduction in SHIV-positive nonhuman primates via long-acting subcutaneous tenofovir alafenamide fumarate release from a nanofluidic implant","volume":"12","author":"Pons-Faudoa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0210","article-title":"Early divergent host responses in SHIVsf162P3 and SIVmac251 infected macaques correlate with control of viremia","volume":"6","author":"Xu","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.jconrel.2023.12.031_bb0215","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00133-22","article-title":"Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile from approved nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"66","author":"Diamond","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01167-21","article-title":"Development of human immunodeficiency virus type 1 resistance to 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine starting with wild-type or nucleoside reverse transcriptase inhibitor-resistant strains","volume":"65","author":"Cilento","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0225","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1093\/jac\/dky256","article-title":"Antiretroviral potency of 4\u2032-ethnyl-2\u2032-fluoro-2\u2032-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtype s","volume":"73","author":"Njenda","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0230","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/jac\/dkx280","article-title":"M184I\/V substitutions and E138K\/M184I\/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA","volume":"72","author":"Oliveira","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0235","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cid\/ciy453","article-title":"Trends in the molecular epidemiology and genetic mechanisms of transmitted human immunodeficiency virus type 1 drug resistance in a large US clinic population","volume":"68","author":"Rhee","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0240","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0245","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0250","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/QAI.0000000000002879","article-title":"Brief report: efficacy and safety of oral islatravir once daily in combination with doravirine through 96 weeks for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine","volume":"91","author":"Molina","year":"2022","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0260","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2023.04.037","article-title":"Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates","volume":"358","author":"Pons-Faudoa","year":"2023","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2023.12.031_bb0270","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2020.07.2326","article-title":"Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1","volume":"110","author":"Liu","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2023.12.031_bb0275","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.037","article-title":"2-Hydroxypropyl-beta-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis","volume":"306","author":"Pons-Faudoa","year":"2019","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923008155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923008155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:43:15Z","timestamp":1777509795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923008155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":58,"alternative-id":["S0168365923008155"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}